Maryam K. Fard

Maryam K. Fard

Auto-generated profile, based on publicly available information

Maryam K. Fard

Max Planck Institute for Experimental Medicine, 37075 Göttingen, Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MFMaryam K. Fard
Maryam K. Fard
FMFranziska van der Meer
Franziska van der Meer
PSPaula Sánchez
Paula Sánchez
LCLudovico Cantuti-Castelvetri
Ludovico Cantuti-Castelvetri
SMSunit Mandad
Sunit Mandad
MSMikael Simons
Mikael Simons
Investigations into brain function and disease depend on the precise classification of neural cell types. Cells of the oligodendrocyte lineage differ greatly in their morphology, but accurate identification has thus far only been possible for oligodendrocyte progenitor cells and mature oligodendrocytes in humans. We find that breast carcinoma amplified sequence 1 (BCAS1) expression identifies an oligodendroglial subpopulation in the mouse and human brain. These cells are newly formed, myelinating oligodendrocytes that segregate from oligodendrocyte progenitor cells and mature oligodendrocytes and mark regions of active myelin formation in development and in the adult. We find that BCAS1+ oligodendrocytes are restricted to the fetal and early postnatal human white matter but remain in the cortical gray matter until old age. BCAS1+ oligodendrocytes are reformed after experimental demyelination and found in a proportion of chronic white matter lesions of patients with multiple sclerosis (MS) even in a subset of patients with advanced disease. Our work identifies a means to map ongoing myelin formation in health and disease and presents a potential cellular target for remyelination therapies in MS.